- Q3 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 14, 2024$1.59 (-2.45%)Earnings
- Q2 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 14, 2023$1.45 (+20.83%)Earnings
- Q1 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2023$2 (-0.99%)Earnings
- Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research TranscriptJul 19, 2023
- Q4 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 07, 2023$2.99 (-1.32%)Earnings
- Immunoprecise Antibodies Ltd at Smallcap Discoveries TranscriptJun 28, 2023
- Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q3 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 16, 2023$3.37 (-10.13%)Earnings
- Q2 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 15, 2022$4.9 (-8.58%)Earnings
- Q1 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2022$4.85 (-9.85%)Earnings
- Q4 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 29, 2022$4.23 (-7.03%)Earnings
- Q2 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 13, 2021$5.06 (-9.96%)Earnings
- Immunoprecise Antibodies Ltd LifeScience Webinar TranscriptApr 28, 2021
Q3 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Good morning, and welcome to IPA's earnings call for the third-quarter fiscal year 2023. I am Regina, and I will be your host for today's call.
Before we begin, I would like to remind everyone that our remarks today may include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in our statements. We encourage you to review our filings with the Securities and Exchange Commission for a more complete discussion of these risks and uncertainties. IPA undertakes no obligation to update these forward-looking statements, except as required by law.
On today's conference call and the accompanying presentation slides, non-GAAP financial measures will be used to help investors and analysts understand IPA's business performance. IPA believes adjusted EBITDA reflects the business in a manner that allows for a meaningful period-to-period comparisons and analysis of trends in its business. An explanation and reconciliation of non-GAAP to GAAP measures can be found in the text of our management
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)